Article
Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Cancer immunology, immunotherapy : CII - 1 Nov 2018
Yao Yu, Luo Feifei, Tang Chao, Chen Dikang, Qin Zhiyong, Hua Wei, Xu Ming, Zhong Ping, Yu Shuangquan, Chen Di, Ding Xiaojie, Zhang Yi, Zheng Xiujuan, Yang Jiao, Qian Jiawen, Deng Yuting, Hoon Dave S B, Hu Jian, Chu Yiwei, Zhou Liangfu
Abstract excerpt
Dendritic cell (DC)-based vaccination is a promising approach for active-specific immunotherapy, but is currently of limited efficacy. The safety and effectiveness of a DC vaccine (DCV) loaded with glioblastoma stem cell-like (GSC) antigens was assessed in glioblastoma multiforme (GBM) patients. In this double-blind, placebo-controlled phase II clinical trial, 43 GBM patients were randomized after surgery at a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.